Key result
Retigabine and gabapentin restored K+ currents and reduced neuronal firing to nearly normal levels in cells expressing the epilepsy-associated dominant-negative KCNQ5 R359C variant.
Why the study?
Loss-of-function variants in KCNQ5 were identified in genetic generalized epilepsy, prompting investigation into whether KV7 channel openers could restore channel function and neuronal firing.
Do KV7 channel openers (retigabine, gabapentin) restore channel function and neuronal firing in cells expressing the epilepsy-associated KCNQ5 R359C variant?
Do KV7 channel openers (retigabine, gabapentin) restore channel function and neuronal firing in cells expressing the epilepsy-associated KCNQ5 R359C variant?
KV7 channel openers like retigabine and gabapentin can restore channel function and normalize neuronal firing in the epilepsy-associated KCNQ5 R359C variant, suggesting a potential targeted therapy for affected patients.
No takes yet. Share an insight, caveat, or question.
KCNQ5 loss-of-function variants warrant further epilepsy modeling; leaves open targeted pharmacological rescue for dominant-negative mutations.
Krüger et al. (2023) studied genetic generalized epilepsy. Retigabine and gabapentin vs. absence of drugs was evaluated on K+ current density, M-current amplitudes, and neuronal firing. Retigabine and gabapentin restored K+ currents and reduced neuronal firing to nearly normal levels in cells expressing the epilepsy-associated dominant-negative KCNQ5 R359C variant.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: